Anti-Androgen Receptor (phospho S210 + S213) antibody [156C135.2] (ab45089)

Overview

  • Product nameAnti-Androgen Receptor (phospho S210 + S213) antibody [156C135.2]
    See all Androgen Receptor primary antibodies
  • Description
    Mouse monoclonal [156C135.2] to Androgen Receptor (phospho S210 + S213)
  • Tested applicationsSuitable for: WB, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Rat, Rabbit, Horse, Guinea pig, Hamster, Cat, Dog, Pig, Chimpanzee, Monkey, Baboon, Cynomolgus Monkey, Hedgehog, Rhesus monkey
  • Immunogen

    Synthetic phosphopeptide:

    GRAREASGAPTSSKD

    , corresponding to amino acids 207-221 of Human Androgen Receptor

  • Positive control
    • IGF1 stimulated LNCaP cells. IHC-P: human normal prostate FFPE tissue sections
  • General notes


    In IGF-1 stimulated LNCaP cells (passage number 38), a ~110 kDa band was observed. The serine phosphorylation site recognized by ab45089 has been alternatively referred to Ser213 (Lee and Chang, 2003) and Ser210 (Lin et al, 2003). Variations in denotation can arise from how the sequence is counted in various GenBank accession numbers. The site is denoted as Ser213 in GenBank Accession No. A39248, which was used to design the immunogen.

Properties

Applications

Our Abpromise guarantee covers the use of ab45089 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 - 4 µg/ml. Detects a band of approximately 110 kDa (predicted molecular weight: 99 kDa).
IHC-P Use a concentration of 10 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Target

  • FunctionSteroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
    Isoform 3 and isoform 4 lack the C-terminal ligand-binding domain and may therefore constitutively activate the transcription of a specific set of genes independently of steroid hormones.
  • Tissue specificityIsoform 2 is mainly expressed in heart and skeletal muscle (PubMed:15634333). Isoform 3 is expressed by basal and stromal cells of prostate (at protein level) (PubMed:19244107).
  • Involvement in diseaseAndrogen insensitivity syndrome
    Spinal and bulbar muscular atrophy X-linked 1
    Defects in AR may play a role in metastatic prostate cancer. The mutated receptor stimulates prostate growth and metastases development despite of androgen ablation. This treatment can reduce primary and metastatic lesions probably by inducing apoptosis of tumor cells when they express the wild-type receptor.
    Androgen insensitivity, partial
  • Sequence similaritiesBelongs to the nuclear hormone receptor family. NR3 subfamily.
    Contains 1 nuclear receptor DNA-binding domain.
  • DomainComposed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain. In the presence of bound steroid the ligand-binding domain interacts with the N-terminal modulating domain, and thereby activates AR transcription factor activity. Agonist binding is required for dimerization and binding to target DNA. The transcription factor activity of the complex formed by ligand-activated AR and DNA is modulated by interactions with coactivator and corepressor proteins. Interaction with RANBP9 is mediated by both the N-terminal domain and the DNA-binding domain. Interaction with EFCAB6/DJBP is mediated by the DNA-binding domain.
  • Post-translational
    modifications
    Sumoylated on Lys-388 (major) and Lys-521. Ubiquitinated. Deubiquitinated by USP26. 'Lys-6' and 'Lys-27'-linked polyubiquitination by RNF6 modulates AR transcriptional activity and specificity.
    Phosphorylated in prostate cancer cells in response to several growth factors including EGF. Phosphorylation is induced by c-Src kinase (CSK). Tyr-535 is one of the major phosphorylation sites and an increase in phosphorylation and Src kinase activity is associated with prostate cancer progression. Phosphorylation by TNK2 enhances the DNA-binding and transcriptional activity and may be responsible for androgen-independent progression of prostate cancer. Phosphorylation at Ser-83 by CDK9 regulates AR promoter selectivity and cell growth. Phosphorylation by PAK6 leads to AR-mediated transcription inhibition.
    Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.
  • Cellular localizationNucleus. Cytoplasm. Predominantly cytoplasmic in unligated form but translocates to the nucleus upon ligand-binding. Can also translocate to the nucleus in unligated form in the presence of RACK1.
  • Information by UniProt
  • Database links
  • FormThere are 2 isoforms produced by alternative splicing. Isoform 1 is also known as: AR-B; isoform 2 is known as AR-A or variant AR45.
  • Alternative names
    • AIS antibody
    • ANDR_HUMAN antibody
    • Androgen nuclear receptor variant 2 antibody
    • Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease) antibody
    • Androgen receptor antibody
    • androgen receptor splice variant 4b antibody
    • AR antibody
    • AR8 antibody
    • DHTR antibody
    • Dihydro testosterone receptor antibody
    • Dihydrotestosterone receptor (DHTR) antibody
    • Dihydrotestosterone receptor antibody
    • HUMARA antibody
    • HYSP1 antibody
    • KD antibody
    • Kennedy disease (KD) antibody
    • NR3C4 antibody
    • Nuclear receptor subfamily 3 group C member 4 (NR3C4) antibody
    • Nuclear receptor subfamily 3 group C member 4 antibody
    • SBMA antibody
    • SMAX1 antibody
    • Spinal and bulbar muscular atrophy (SBMA) antibody
    • Spinal and bulbar muscular atrophy antibody
    • Testicular Feminization (TFM) antibody
    • TFM antibody
    see all

Anti-Androgen Receptor (phospho S210 + S213) antibody [156C135.2] images

  • All lanes : Anti-Androgen Receptor (phospho S210 + S213) antibody [156C135.2] (ab45089) at 1 µg/ml

    Lane 1 : LNCaP cells with serum starved cells
    Lane 2 : LNCaP cells with IGF1 incubated for 4h at 0.1 µg/ml
    Lane 3 : LNCaP cells with incubated with 20 ug LY294002 for 30 min then IGF1 incubated for 4h at 0.1 µg/ml


    Predicted band size : 99 kDa
    Observed band size : 110 kDa (why is the actual band size different from the predicted?)
  • IHC image of Androgen Receptor (phospho S213 + S210) staining in human normal prostate formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab45089, 10µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

References for Anti-Androgen Receptor (phospho S210 + S213) antibody [156C135.2] (ab45089)

This product has been referenced in:
  • Robitaille CN  et al. Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells. Toxicol Sci 143:126-35 (2015). Read more (PubMed: 25324206) »
  • Agapova OA  et al. A neuroactive steroid 5alpha-androstane-3alpha,17beta-diol regulates androgen receptor level in astrocytes. J Neurochem 98:355-63 (2006). Read more (PubMed: 16638015) »

See all 5 Publications for this product

Product Wall

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (PC3 Prostate cancer cell line)
Permeabilization Yes - 0.1% v/v TritonX-100
Specification PC3 Prostate cancer cell line
Blocking step BSA as blocking agent for 20 minute(s) · Concentration: 5% · Temperature: RT°C
Fixative Paraformaldehyde
Username

Dr. Dimitra Kalamida

Verified customer

Submitted May 30 2016

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"